We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it has completed its acquisition of Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato), a biopharmaceutical...
KING OF PRUSSIA, Pa., Sept. 11 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) announces that the waiting period under the Hart-Scott-Rodino Antitrust...
KING OF PRUSSIA, Pa., Aug. 18 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato: MICU) announced today it filed a New Drug Application (NDA) with the U.S. Food...
KING OF PRUSSIA, Penn., Aug. 15 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals (Nasdaq: MICU; Nuovo Mercato) announced that its stockholders have voted to approve the merger agreement...
KING OF PRUSSIA, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (NASDAQ:MICUNASDAQ:NuovoNASDAQ:Mercato) today reported financial results for the second quarter ended June 30...
Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-Infectives Vicuron Products Anidulafungin and Dalbavancin Under Review by U.S. Food and Drug Administration NEW...
Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark Office KING OF PRUSSIA, Penn., June 2 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc...
Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal Candidiasis KING OF PRUSSIA, Pa., May 31 /PRNewswire-FirstCall/ -- Vicuron...
Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific Growth Equities Annual Life Sciences Growth Conference KING OF PRUSSIA...
Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech Conference KING OF PRUSSIA, Pa., May 17 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq and Nuovo Mercato: MICU...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions